developed from the science called Neuroplasticity
Brainberry Ltd, the developer of COSMA, is under continuous clinical studies to determine the validity of the COSMA therapy in dementia patients.
Quality of Life
The current clinical trials are focusing on how COSMA can positively impact upon the four elements below in relation to helping people with Dementia.
Preliminary Trials – COSMA Therapy with healthy volunteers – 2018
Phase II – COSMA Neurofeedback Headset trials with Dementia Patients – 2021
COSMA is constantly evolving, the scientific data available within the therapy will allow COSMA to influence and lead future developments in Dementia treatments.
We at Brainberry, the brains behind COSMA, are already working on numerous projects, all of which are designed to integrate seamlessly into the COSMA therapy, which will further advance both the technology and treatment opportunities for people with Dementia and other similar mental health ailments.
To celebrate COSMA's launch, we are offering the first 100 users a SPECIAL PRICING on our therapy packages. This is on a first come first served basis, so be quick to sign up and receive the COSMA package.